EW - Here's Why Edwards Lifesciences Stock Rose 52.3% in 2019
Shares of Edwards Lifesciences (NYSE: EW) soared over 52% last year, according to data provided by S&P Global Market Intelligence. The company, which specializes in medical devices used to address structural heart disease, delivered impressive revenue gains and steadily improved full-year 2019 guidance with each quarterly update. That allowed the growth stock to easily beat the 28.8% rise of the S&P 500 in 2019.
Management believes growth should continue for the foreseeable future. As of December, Edwards Lifesciences expected to reach the top end of its full-year 2019 revenue guidance range of $4 billion to $4.3 billion. The company sees revenue increasing 10% to 12% in 2020.
Image source: Getty Images.